CNDO did NOT "swap" endpoints as tweeted by Fuerstein. The endpoints reported are endpoints relating to repetitive and disruptive behaviors just as listed on the govt website. There are multiple MEASURES for those same behaviors After an INTERIM analysis the study reached statistical significance after only 5 subjects for 3 measures of those endpoints with significant separation from placebo for 5 out of 5 subjects. The measures reported in the press release were additional measures of the same behavior also properly used for study by the investigator but are not all the exact measures listed on the govt site ,So whereas for example 2 other measures of "rigidity" have already met stat significance with separation of 5 out of 5, the YBOCS measure for rigidity listed on the website perhaps is at 3 or 4 out of 5, and needs the full 10 studied to reach stat significance. If you look at Hollanders lecture from a couple months ago you will see he does mention separation for multiple patients for the measures listed on the govt website (YBOCS, ABC, etc). All CNDO did was report data that Hollander himself reported so far. They didn't "swap" endpoints for autism as falsely tweeted. Fuerstein wants CNDO to fail. He supports the short interest and/or took a childish and uneducated early view of TSO and spews self serving nonsense to support it. The notion that CNDO "swapped endpoints" is completely false. Rather they reported the measures that Hollander himself has reported the results for so far, which do measure the same endpoints. Where was AF's precision when "The Street" totally and completely mischaracterized the Crohn's results, stating that they showed absolutely no efficacy at all? That was completely untrue for 2 of 3 subsets. The interim autism results are extremely positive. In any event the PPS faded Friday on short manipulation, as shorts try to maintain control. Nothing more and nothing less.
Sentiment: Strong Buy
They can't buy or sell. They have insider info on 3 different study indications right now. Crohn's, Autism, and Psoriasis. Very few details known by the public, even for the failed but still unpublished Crohn's study.
Sentiment: Strong Buy
This was already answered shorty. Because insiders can't buy they have insider info including the unpublished results from the Crohn's study. You want to ask again? COVER WHILE YOU CAN.
They won't because they can't. Still have inside info even from the unpublished Crohn's results. Shorts had their day and its over. Cover while you can pal. EOM.
Sentiment: Strong Buy
LOL. You would collect on that bet probably within a couple weeks. (and unless pcyc goes to zero you would both have to be dead for you to have to pay up).
Physicians will prescribe off label immediately for all indications, imho. But do need the formal approval for the increased marketing power etc.
This company isn't going anywhere. (ie;its here to stay for a while). It's recent hiring/firing activity confirms that. Plus it would be ridiculous for them not to wait for outcome for some ongoing clinical trials. Nobody is buying back shares or issuing dividends. That's ridiculous, They need to preserve cash. The MS trial is a 2 year ordeal that will readout approximatelly from mid april to late may 2014, My source for that is at the highest levels. I understand for new positions the speculation about bounces from 1.40 etc. but that doesn't interest me. I will check back from time to time and if anyone has any info on when any other trials will read out (psoriasis, autism, UC, or anything else) please post it. These are really the only things that matter to pre-crohns release longs. Catalysts catalysts catalysts. Things that validate the science will determine the future of this company. Despite the Crohn's dissapointment, there is a strong basis for optimism re the science and several shots on goal remain. I also may check back to comment on any details from the Crohns results, if we ever friggin are told what they are. GLTA new and old longs.
Like I said reasonable minds can differ. The presentation mostly was about crohns and UC, and absent details about the new crohns results, which are potentially/probably somewhat inconsistent with the open label results, I think the responsible thing, so as not to mislead, is to take it down. We can agree to disagree on this one no biggie...
So, previously was posted that Kevin Horgan (new hire head of scientific affairs etc) looked like one of Harlan's guys (bc of his Centocor background). Well, i looked a little further and not only that, Horgan designed the clinical trials for REMICADE!!! Do you think Harlan wants to get it right next time? This also is a strong indicator that Harlan is here to stay. He is not going to hire his old Centocor/Remicade buddy just to opt out himself. Also see that among the multiple fire-ees are old Rosenwald guys. Harlan Weisman is clearly fully in charge and it looks like he is here to stay. Patience on this one may still prove profitable. Of course i am a big loser so far with CNDO so require a lot more patience then the new longs.
Reasonable minds can differ but i think the presentations should be down. Regardless, if you are e-mailing IR maybe would be more productive to inquire re when they expect the next clinical trial to be completed and to be announced, and for which indication...or when they expect to announce details of TRUST-1. Not criticizing you here but if we are going to ask them to expend resources to inform us, there are IMHO more important things we could be addressing.
yes and the CEO's presentations always had slides where he went through and discussed the various patents and intellectual property rights, Some of it is licensed from Falk Pharma and covers the USA and Japan while Falk keeps Europe. The presentations from the website probably are down now so as not to mislead until the newest data is published.
Turtle-if company shut down today you would get over $2.25/sh for the shares you own. The cash would be disbursed to the shareholders. In principal the negative valuation is based on notion that 1) company will keep going and 2) the trials will fail, so then the company is worth less than cash. Such valuations are usually assigned to companies with untrustworthy management who just string out the inevitable while they get paid their hefty salaries. As previously discussed, it's totally inappropriate for a company run by this particular CEO.
Either the planned clinical trials for TSO will read out positive, or not. You should have results regarding MS, autism, and psoriasis i believe in that time frame. MS HINT 2 trial is important. 15 subjects (5 done 10 to go) but they follow the patients for like 20 months and despite a sample size that sounds small, if the next 10 read out like the first 5, and if you understand what and how they are testing, it would be quite statistically significant. You can google and read about it. I guess zero is a slight exaggeration they still will have the cancer cell biologic, but no data on that until 2015. This company is not a 10 drug company. It has 2 biologics, each with multiple shots on goal.